With respect to cardiac development, LTB is identified as a risk factor altered for cardiovascular diseases and thus the TNF antagonist potentially acts as a likely candidate to reduce the CVD risk in rheumatoid arthritis patients52–55. This evidence concerns the gene LTB and rheumatoid arthritis.